ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 258

Health Services Utilization as Recommended by the American Diabetes Association Among Middle-Aged Patients Disabled with Rheumatoid Arthritis and Diabetes Mellitus

Geyanne Lui1, Mangala Rajan 1, Lisa Kern 1, Laura Pinheiro 1, Monika Safford 1, Jeffrey Curtis 2 and Iris Navarro-Millan 1, 1Weill Cornell Medicine, New York, 2University of Alabama at Birmingham, Birmingham, AL

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: clinical practice guidelines and health disparities, health services utilization, Medicare, Rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: Health Services Research Poster I – ACR/ARP

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Medicare beneficiaries who are disabled (coverage by the Social Security Disability Insurance (SSDI)) with rheumatoid arthritis (RA) and diabetes mellitus (DM) and under 65 years of age are complex patients with heavy healthcare use. These young disabled patients cost 31% more than older Medicare patients, but we do not know whether they are receiving the basic standards of diabetes care given their disability and complexities related to also having RA. Our purpose was to assess the standard of care for diabetes measured by health services utilization in patients under 65 years of age who are disabled with RA and DM by race and ethnicity.

Methods: We conducted a longitudinal analysis from 2010– 2014 of patients who were beneficiaries of the SSDI with both RA and DM. RA was defined in 2010 as either 1) two RA diagnoses (ICD9-714.xx) by a rheumatologist between 7 and 365 days apart; OR 2) one RA diagnosis by a rheumatologist and at least 1 prescription for a disease modifying anti-rheumatic drug. DM was defined as one diagnosis from any physician (ICD-9 250.xx) in 2010. Patients were followed for 4 years (2011 – 2014) and outcomes were the testing and visit standards defined by the 2010 American Diabetes Association. We used Poisson models to adjust for age, gender, and Charlson-Deyo Comorbidity Index and examined the differences between racial/ethnic groups.

Results: In 2010, there were 5,380 patients under the age of 65 disabled with RA and DM receiving SSDI benefits. The cohort was 78% female and 61% had 5 or more comorbidities. These patients had high health services utilization with a mean number of visits to the doctor of about 18 visits a year (Table 1). More than half (53.5%) of all patients did not receive a foot exam and almost a quarter (23.3%) did not receive an eye exam in 2011-2014. After multivariable adjustment, Hispanic patients had a statistically significant higher annual mean of testing (HbA1c 2.39 vs 2.19, urine albuminuria 2.8 vs 2.28, and lipid 1.96 vs 1.67) than White patients in 2011-2014 (Table 2). Both Hispanic and Black patients had a higher annual mean of eye exams (1.16 and 1.03, respectively, vs 0.88) but lower annual mean of foot exams (1.01 and 1.04, respectively, vs 1.18) than the White patients.

Conclusion: Disabled patients with RA and DM had high utilization of health services and received most of the recommended standard of care for diabetes, which was similar across all racial/ethnic groups. The exception was for eye exams, which was lower among Whites. However, there was low utilization of specialty services related to DM care such as ophthalmology evaluations or foot exams by any physician.


ACR_2019_abstract_SoC_table 1


ACR_2019_abstract_SoC_table 2


Disclosure: G. Lui, None; M. Rajan, None; L. Kern, None; L. Pinheiro, None; M. Safford, Amgen, 2, 9; J. Curtis, AbbVie, 2, 5, Abbvie, 2, 5, AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Lilly, Janssen, Myriad, Pfizer, Regeneron, Roche, and UCB, 2, 5, Amgen, 2, 5, Amgen Inc., 2, 5, BMS, 2, 5, Bristol-Myers Squibb, 2, 5, Corrona, 2, 5, Crescendo, 2, 5, Eli Lilly, 2, 5, Eli Lilly and Company, 2, 5, Genentech, 2, 5, Janseen, 5, Janssen, 2, 5, Janssen Research & Development, LLC, 2, Lilly, 2, 5, Myriad, 2, 5, Patient Centered Outcomes Research Insitute (PCORI), 2, Pfizer, 2, 5, Radius Health, Inc., 9, Regeneron, 2, 5, Roche, 2, 3, 5, Roche/Genentech, 5, UCB, 2, 5; I. Navarro-Millan, None.

To cite this abstract in AMA style:

Lui G, Rajan M, Kern L, Pinheiro L, Safford M, Curtis J, Navarro-Millan I. Health Services Utilization as Recommended by the American Diabetes Association Among Middle-Aged Patients Disabled with Rheumatoid Arthritis and Diabetes Mellitus [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/health-services-utilization-as-recommended-by-the-american-diabetes-association-among-middle-aged-patients-disabled-with-rheumatoid-arthritis-and-diabetes-mellitus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/health-services-utilization-as-recommended-by-the-american-diabetes-association-among-middle-aged-patients-disabled-with-rheumatoid-arthritis-and-diabetes-mellitus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology